ArticleInflammatory bowel diseases2022

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.

Jurij Hanzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.